Get the Stockscreener App
2.43
0.41%
-0.010
Pre-market:
2.39
-0.04
-1.65%
Context Therapeutics Inc stock is traded at $2.43, with a volume of 1.43M.
It is down -0.41% in the last 24 hours and up +63.09% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$2.44
Open:
$2.44
24h Volume:
1.43M
Relative Volume:
1.05
Market Cap:
$223.27M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-2.6703
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+7.52%
1M Performance:
+63.09%
6M Performance:
+257.35%
1Y Performance:
+203.75%
1-Day Range:
$2.40
$2.58
1-Week Range:
$2.02
$2.58
52-Week Range:
$0.49
$2.85
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.43 | 224.19M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance
THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Sahm
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
TELA Bio Grants Equity to New Hires as Medtech Growth Push Continues - mychesco.com
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
Ideas Watch: How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) stock: surges after-hours ahead of key Phase 3 results webcast - parameter.io
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com
AI Stocks: Can TRTX deliver consistent dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent - MyChesCo
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Aug PostEarnings: Is Context Therapeutics Inc. likely to announce a buyback2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Sandoz Group (OTCMKTS:SDZNY) versus Context Therapeutics (NASDAQ:CNTX) Head-To-Head Contrast - Defense World
emerging us stocks2025 Price Targets & Verified Technical Trade Signals - Bollywood Helpline
Ideas Watch: How does Context Therapeutics Inc perform in inflationary periodsMarket Trend Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Contineum Therapeutics Reports Phase 2 Trial Results - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
DFTX Stock Price, News & Analysis - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
CEO Moves: Can Context Therapeutics Inc. stock double in the next year2025 Market Sentiment & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Revenue Check: Does Consensus Cloud Solutions Inc stock trade at a discount to peers2025 Volume Leaders & Stock Timing and Entry Methods - Bộ Nội Vụ
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Will Context Therapeutics Inc. stock benefit from automationPortfolio Gains Summary & Risk Adjusted Swing Trade Ideas - Улправда
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Context Therapeutics Inc.Common Stock (NQ: CNTX - FinancialContent
User | inyoregister.comContext Therapeutics Inc.Common Stock (Nasdaq:CNTX) Stock Quote - FinancialContent
Pasadena Star News - FinancialContent
Moving Average Crossover Confirms Uptrend in Manugraph India LimitedFederal Reserve Announcements & Breakout Portfolio Performance - bollywoodhelpline.com
About Us - FinancialContent
Can Context Therapeutics Inc. stock hit record highs againWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Will Theranexus Société Anonyme (3VG) stock beat value stocks2025 Big Picture & Proven Capital Preservation Methods - ulpravda.ru
Why Context Therapeutics Inc. stock is trending among retail tradersJuly 2025 Rallies & Weekly Breakout Watchlists - Улправда
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):